**WEB REQUIREMENTS**

|  |  |  |  |
| --- | --- | --- | --- |
| **Project Name (internal)** | Gyn Dinner Symposium | **Project Code** | PB5LSS016 |
| **Virtual Project Manager** | Choose an item. | **Clinical Program Manager** | Amy Furedy |
| **Compliance** | Susan Yarbrough | **Editor** | Trudy Stoddert |

**Launch Date/Internal Launch Date:**

**Project Type**

Webcast

Downloadable Slides

CD/DVD

Podcast

Other:

**Email Blast Included?**

Yes

No

**Number of E-Blasts**

Only One

Two

Three  
Other Amount:

Dates to Blast or Special Requests:

**Cross Promotion**

Yes

No

If Yes, List Activities:

**Target Audience**

US  
EX-US  
Global (Both EX-US & US)  
Other or Special:

Additional Emails (Supporters?):

**Slides**

Slides Included

Yes

No

Slide Location:

Slides Available By:

**Slides Synched? (if included in webcast)**

Yes

No

**Webpage Content (All Copy)**

Content Status (Final/Approved):

**CME?**

Yes

No

**CME Posttest Link:**

**Webcast/PDS URL:**

**Additional Components**

Cases with Voting

Polls

Video Segmentation

Table of Contents

Other:

**Mobile App Title:**

**LIVE MEETING-ASSOCIATED VIRTUAL ACTIVITIES**

**WEB URL: <http://www.primeoncology.org/dinnersymposium_barcelona_2015_webcast>**

1. **Integrating New Therapies Into Ovarian Cancer Management: Does *BRCA* Status Matter?**

**ACTIVITY FEATURES**

[Icon] Interactive Presentation

[Icon] Downloadable Slides

[Insert screen shot]

1. **ACTIVITY OVERVIEW**

This Webcast contains **video and downloadable slides** from the symposium Integrating New Therapies Into Ovarian Cancer Management: Does BRCA Status Matter?, a prIME Oncology educational activity that was held on Friday, 16 January 2015 at the *2015 Progress and Controversies in Gynecologic Oncology Conference* in Barcelona, Spain.

1. **PROVIDER**

This activity is provided by prIME Oncology.

1. **SUPPORTER**

This educational activity is supported by AstraZeneca.

1. **TOPICS**

Advanced ovarian cancer: Why should I recommend *BRCA* testing?

*Judith Balmaña, MD, PhD*

Personalizing treatment of relapsed ovarian cancer: What is the evidence?

*Jonathan Ledermann, MD, FRCP*

A look to the future: How to integrate new agents into the current treatment algorithm?

*Nicoletta Colombo, MD*

**7. FACULTY**

**Nicoletta Colombo, MD**

University of Milano-Bicocca

European Institute of Oncology

Milan, Italy

**Judith Balmaña, MD, PhD**

Vall d’Hebron University Hospital

Barcelona, Spain

**Jonathan Ledermann, MD, FRCP**

UCL Cancer Institute

University College London

London, United Kingdom

**8. TARGET AUDIENCE**

This Webcast is intended for gynecologists, oncologists, radiation therapists, surgeons, pathologists, and other practitioners including allied health professionals involved in the diagnosis and management of gynecologic malignancies.

**9. LEARNING OBJECTIVES – please check if any of these should be deleted**

Upon completion of this educational activity, participants should be able to:

* Evaluate emerging data regarding the significance of *BRCA* gene mutations in the management of advanced ovarian cancer and the role of testing for this biomarker in clinical practice
* Employ personalized treatment strategies when choosing optimal treatment regimens for patients with advanced ovarian cancer
* Integrate novel agents into the treatment algorithm for patients with advanced ovarian cancer

**13. ACTIVITY DATE**

Release Date

XX February 2015

Expiration Date

XX February 2016

**14. MOBILE APP VIEW ACTIVITY TEXT PER VIDEO**Insert presentation-specific text for the “View Activity” action item on the mobile app. *[copy from live meeting - the symposia webcast mobile app titles are exactly the same as the symposia app title (since once the live meeting has occurred, that title is no longer in use and it is easier for users to associate the enduring activity with the live activity that way.]*

*Gyn Congress Dinner Symp*

1. **Web Activity Page Titles**

Landing Page Title: *Integrating New Therapies Into Ovarian Cancer Management: Does BRCA Status Matter?*  
Activity Page Title: *[Presentation Titles]*

1. **Meta Description  
   This activity features video and downloadable slides from the prIME Oncology symposium,** *Integrating New Therapies Into Ovarian Cancer Management: Does BRCA Status Matter?,* held in January 2015 in Barcelona.

**Key Words and Key Phrases  
(Please included as many key words or phrases as are associated with the activity. 15 or more is ideal. These are words or phrases that a viewer might use in a web search. Please add one key word/phrase per line) Example:** ovarian cancer

BRCA

BRCA mutation

BRCA-related ovarian cancer

BRCA 1/2

PARP inhibitor

olaparib

genetic mutation

genetic testing

serous ovarian cancer

germline mutation

platinum-based therapy

homologous recombination

genetic counseling

DNA damage repair pathways

Platinum-sensitive

Partially platinum-sensitive

Platinum-resistant

Treatment algorithm

Bevacizumab

Maintenance

Rucaparib

Study 19

Solo 1

Solo 2

1. **[Meeting-Associated Podcast]---VERIFY with Clinical after the meeting to see what presentation are to be included**
2. **E-blast Subject Header**

New Webcast: Integrating New Therapies Into Ovarian Cancer Management: Does BRCA Status Matter?